Trial Profile

A Phase III clinical trial of therapeutic HIV vaccine

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Dec 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LC 002 (Primary)
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Sponsors Genetic Immunity

Most Recent Events

19 Dec 2018 New trial record
18 Dec 2018 According to a Genetic Immunity media release, in this study patients are expected to be enrolled in H1-2019 and to be completed in H1-2020.
05 Dec 2018 According to a Genetic Immunity media release, this trial will be conducted at the Moscow City Center for the Prevention and Control of AIDS. Upon successful completion of this trial, the company plans to apply for marketing approval in the Commonwealth of Independent States (CIS) (formerly Soviet Union) region.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com